Cargando…
Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial
BACKGROUND: Glioblastoma (GBM) is a highly virulent tumor of the central nervous system, with a median survival < 15 months. Clearly, an improvement in treatment outcomes is needed. However, the emergence of these malignancies within the delicate brain parenchyma and their infiltrative growth pat...
Autores principales: | Kong, Lin, Gao, Jing, Hu, Jiyi, Lu, Rong, Yang, Jing, Qiu, Xianxin, Hu, Weixu, Lu, Jiade J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383247/ https://www.ncbi.nlm.nih.gov/pubmed/30786916 http://dx.doi.org/10.1186/s40880-019-0351-2 |
Ejemplares similares
-
Carbon-ion radiotherapy boost with standard dose proton radiation for incomplete-resected high-grade glioma: a phase 1 study
por: Qiu, Xianxin, et al.
Publicado: (2022) -
Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma
por: Kong, Lin, et al.
Publicado: (2016) -
Carbon-ion radiotherapy in the treatment of radiation-induced second primary malignancies
por: Yang, Jing, et al.
Publicado: (2022) -
The role of carbon-ion radiotherapy in the treatment of adenoid cystic carcinoma of the nasopharynx
por: Hu, Jiyi, et al.
Publicado: (2022) -
Perfusion MR prior to radiotherapy is a strong predictor of survival in high-grade gliomas after proton and carbon ion radiotherapy
por: Qiu, Xianxin, et al.
Publicado: (2022)